Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
about
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosisA Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-AnalysisInhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidicDoes pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, CanadaDetermination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric methodSusceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activityActivity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamideIn vitro antimycobacterial activities of pyrazinamide analogsActivity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibilityCharacterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosisMechanisms of Pyrazinamide Action and ResistanceReevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.Evaluation of a radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides.Requirement of the mymA operon for appropriate cell wall ultrastructure and persistence of Mycobacterium tuberculosis in the spleens of guinea pigs.Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern RussiaPhenotypic characterization of pncA mutants of Mycobacterium tuberculosis.Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis.Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosisTuberculosis 2004: challenges and opportunities.Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis.Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254.Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variabilityUse of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility.Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosisHost-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method.Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City.Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains.Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
P2860
Q24538909-5C1FFBBB-8849-49B1-9F41-BF9E47788DD2Q24609567-17E13808-FF86-4704-8556-00CCDE145561Q27011264-C1ECC7F5-2568-459D-8051-1F0446E25959Q28329787-2E6EE8B8-2797-4B3E-A11D-25F7F125BE81Q28333302-C7746196-3F79-43C3-8042-D60A31628D62Q28341391-3563D630-CA33-4CD0-A829-E208F6048FAEQ28343917-DF19A364-5E10-4879-A0FA-ED93B59FF081Q28361066-7849D929-A3B9-4225-A256-79C12862375AQ28366605-E6780FB2-7CCE-446D-A4EA-8EA63C8BA3FBQ28367751-E1E90E97-7FF9-4536-82CF-A71076F45C0BQ28378748-BCB22BAE-52B8-4D0A-B813-86923E1594F1Q28379081-97E40DB9-F4F7-43B9-A880-ED4561F09C23Q28379489-043A3CA6-73D4-40D9-9E54-DFCCE8CC70A7Q29304444-E243DD64-E5F4-4160-893B-AA595D0789CDQ30224832-14A0323E-0BFF-4F1C-851D-7B75A1596C9DQ30373724-006C80D2-576F-401D-9E31-871B873CD26CQ30451283-815029BE-B284-4FD1-925F-A1708C3E325EQ33704769-5F5400C8-858B-4E22-A8AC-40FAB531F74EQ33787470-02F55503-DCF1-4440-BC3C-B777FD30436EQ33855579-FDB16631-8C77-450D-B54F-CE72F582D6C5Q33947806-4085CD39-C24A-4762-8764-B27F082436A5Q33976410-B79304CA-F996-403A-BF5D-9AAE5D5A480AQ33977242-4AF06DF0-F6A2-4B5C-9913-6156727DDD92Q33980394-EFA7A80E-DCBA-4CB4-B382-88D48D288666Q33991596-50478051-7DBA-4533-AB16-5FF59D070A48Q34046282-F9779D81-5BB8-475F-AA0F-D1ED1B9EEDF5Q34494098-60AD4981-6619-4DCD-A023-FFF197554F32Q34655115-649E7EE7-8DDB-4E7A-ABBC-56194C1B55A9Q34933405-59034E76-B3D0-44A9-B3E5-E689D90D6C51Q35342842-DB53FB8D-E96B-4B0B-9FEC-2CB04A742D80Q35532853-142FEC29-A52F-478D-9C4B-382110D77B1BQ35671862-6500C70E-C1C3-4E05-B743-289BE861B3A5Q35689060-8C3E1D56-D221-464A-ADDA-D28228656AF9Q35690257-C0DBF43B-B334-431C-BC49-FBFA449C98A8Q35743972-D295D71F-CF82-475B-A89E-D54967FFBCF9Q35947487-6106D8CD-18A0-471B-824C-F6FEC7B1DA24Q36076037-325DA034-FEF1-4A02-A3F5-AEA3BD3930CAQ36082638-DB3DDDA8-8BE8-4217-A07A-FCBC27BA9161Q36098662-1047BCFB-D27F-4CF3-BDD2-D3B7E9D510F1Q36194929-04CDB18E-5A5B-4860-BB14-3EC65E0C17EB
P2860
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
description
1954 nî lūn-bûn
@nan
1954 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1954 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1954年の論文
@ja
1954年論文
@yue
1954年論文
@zh-hant
1954年論文
@zh-hk
1954年論文
@zh-mo
1954年論文
@zh-tw
1954年论文
@wuu
name
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@ast
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@en
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@nl
type
label
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@ast
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@en
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@nl
prefLabel
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@ast
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@en
Activation of pyrazinamide and nicotinamide in acidic environments in vitro.
@nl
P1476
Activation of pyrazinamide and nicotinamide in acidic environments in vitro
@en
P2093
R TOMPSETT
W McDERMOTT
P304
P577
1954-10-01T00:00:00Z